Trial
NCT03395314
Ketamine in Borderline Personality Disorder
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
Nathan Kline Institute for Psychiatric Research; American Foundation for Suicide Prevention
Condition
Borderline Personality Disorder
Intervention
Ketamine
Why stopped
assessment of project in wake of covid-19 related interruptions
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-26